Floatz logo

89zr-dfo-n-suc-c9scfv

Chondrosarcoma

Var2 PharmaceuticalsradiopharmaceuticalEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Chondrosarcoma cohort.

Asset / SponsorPhaseRating
ag-120
Memorial Sloan Kettering Cancer Center
Phase 2B
Azacitidine
IGM Biosciences, Inc.
Phase 1/2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
Eli Lilly and Company
Phase 1/2CCC
Angiotensin-(1-7)
Wake Forest University Health Sciences
Phase 2CCC
Atezolizumab
National Cancer Institute (NCI)
Phase 2CCC

View all 24 →

Same molecule, other indications

89zr-dfo-n-suc-c9scfv is also rated in:

colon carcinomaDormant
C
Indicative ·
39 / 100
View asset →
rectal carcinomaDormant
C
Indicative ·
39 / 100
View asset →
lung carcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →